About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group aims to unravel the molecular mechanisms of cancer progression and metastasis to identify new diagnostic, prognostic and therapeutic targets in cancer. By combining the knowledge and availability of human tumors in the Pathology department with the expertise of the basic molecular cell biology research group, we focus on:
IP: Matilde Lleonart Pajarin Collaborators: Yoelsis Garcia Mayea, Juan Lorente Guerrero, Sergio Benavente Norza, Josep Castellví Vives, Vicente Peg Camara, GC16173720CARR Definición de mecanismos clave de la multiresistencia de tumores de cabeza y cuello a los tratamientos quimio- y Funding agency: Asociación Española Contra el Cáncer Funding: 380000 Reference: AECC/GCE/2016/LLEONART Duration: 01/10/2016 - 30/09/2022
IP: Carlos Molina Cateriano Collaborators: Santiago Ramon y Cajal Agüeras, Jorge Pagola Pérez Blanca, Carlos Palacio García, Noelia Rodríguez Villatoro, David Rodriguez Luna Funding agency: Fundació La Marató de TV3 Funding: 197973.69 Reference: 20171930 Duration: 01/01/2018 - 31/01/2022
IP: Santiago Ramon y Cajal Agüeras Collaborators: Maria Rosa Somoza Lopez de Haro, Teresa Moline Marimon, Josep Castellví Vives, Stefan Hummer Funding agency: Instituto de Salud Carlos III Funding: 123420 Reference: PI17/02247 Duration: 01/01/2018 - 31/12/2020
IP: José Raul Herance Camacho Collaborators: Ana Lain Fernandez, Vicenç Martínez Ibáñez, Laura Vidal Fornells, Carlos Giné Prades, Roso Marès Pagès, Carolina Aparicio Gomez, nTRACK: Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration.., nTRACK: Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration.., Mario Marotta Baleriola, Itziar Busquets Saez, Manuel López Paredes Funding agency: EUROPEAN COMMISSION Funding: 1063437.5 Reference: NTRACK_H2020NMBP2017 Duration: 01/10/2017 - 31/03/2022
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
Check the current rates for the services offered by the Translational Molecular Pathology research group.
Current Rates
PDF 0.25 MB
Rates Anatomia Patologica VHIR 2021
PDF 0.22 MB
